Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 7/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 7/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584619 | 0.79 | KMT2A (0.40) | — | |
| SCHEMBL4583989 | 0.75 | PTGS2 (0.35) | PTGS2PTGDR2ADORA2AADORA1HCAR3 | |
| SCHEMBL4583984 | 0.75 | PTGS2 (0.35) | PTGS2PTGDR2ADORA2AADORA1HCAR3 | |
| SCHEMBL4583848 | 0.73 | PTGS2 (0.40) | PTGS2PTGDR2ADORA2AADORA1HCAR3 | |
| SCHEMBL3159104 | 0.73 | HCAR3 (0.49) | PTGS2PTGDR2HCAR3 | |
| SCHEMBL28251574 | 0.71 | PARP10 (0.42) | PTGS2PTGDR2ADORA2AADORA1HCAR3 | |
| SCHEMBL5152455 | 0.71 | BMPR1B (0.31) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL12890137 | 0.69 | LMNA (0.48) | — | |
| SCHEMBL31313750 | 0.67 | TYR (0.42) | PTGS2BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL27446368 | 0.66 | PTGS2 (0.40) | PTGS2BMPR1BBMPR1ATGFBR1ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407961-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | PTGS2 379/4885BMPR1B 3464/4885BMPR1A 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.